Charting Advances at CRS - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Charting Advances at CRS
This year's meeting of the Controlled Release Society unveiled a plethora of research insights.


Pharmaceutical Technology
Volume 32, Issue 8


Patricia Van Arnum
The annual meeting and exposition of the Controlled Release Society (CRS) held in New York City last month revealed the diversity and complexity of drug delivery and formulation development when modifying the release of a drug.

Nearly 1000 presentations, including poster sessions, were made during the five-day event. Presentations examined the route of administration (e.g., oral, pulmonary, ocular), delivery systems (e.g., encapsulation, device-based, implantables and injectables, lipid-based, particulate, PEGylation, responsive, and transdermal), materials (e.g., excipients, nanoparticles, novel materials for controlled release, polymers), and molecule types (e.g., nucleotides, peptides, proteins, small molecules, and vaccines) addressed in controlled-release formulations.

This broad range of subjects reveals the growing importance of controlled release in pharmaceutical companies' product strategies. In speaking with a scientist from a Big Pharma company, he pondered on how the role of controlled-release systems has evolved.

"We used to think of controlled release almost as an afterthought. As a product neared the end of its life cycle, developing a controlled-release formulation was a way to extend the life cycle of an [immediate-release] drug. That still may be true, but we now evaluate and consider controlled-release applications much earlier in the product's life cycle and development and see it as an important part of our product strategy."

As drug molecules become more complex and the need to service distinct patient populations increases, controlled-release formulations become an attractive option. Last month's meeting shows that the tools for better understanding and modifying the release characteristics of drugs are meeting that challenge.

Patricia Van Arnum is a senior editor at Pharmaceutical Technology,

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here